The State of the Psychedelic Industry & Open Questions (Video)
In the third video of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look at some broader open questions and potential futures in the psychedelics field via a narrated presentation.
External link. We are not responsible for the content.
Read more ↗More From Psychedelic Alpha
Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published
Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out • RAND Survey: Americans Divi...
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
AtaiBeckley is in structured discussions with pharma companies and royalty investors about a potential partnership fo...
Pα+ February 2026 Psychedelic Bill Roundup
A state-by-state and federal review of psychedelics-related bills introduced or advanced in February 2026, including ...
Latest News
Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols
What gets lost when iboga is reduced to ibogaine, and complex care is reduced to protocol? In this op-ed, Paije West ...
Evaluating the Pros and Cons of State Psychedelic Task Forces
While state legislatures across the U.S. are creating task forces to evaluate proposed legislation to regulate psych...
Scientists test if ketamine has antidepressant effects under anesthesia; France is the first to approve IV ketamine for severe suicidal crisis
Plus: New research on the role of trip sitters; Various state bills move to expand psychedelics research and access
The Life You Call “Normal” Was Designed
Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.
Wait, Are We In a Simulation?
This DMT laser experiment suggests yes, but neuroscientists say probably not. [...] Read More... The post Wait, Are W...
A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter
Dear Colleagues,We write as a collective of practitioners, researchers, clinicians, and integration specialists with ...